MX2014005874A - Formulacion de liberacion inmediata de 4 - metil - 3 - [ [4- (3-piridinil) - 2 - pirimidinil] - amino] - n - [5 - (4 - metil - 1h - imidazol - 1 - il) - 3 - (trifluoro-metil) - fenil] - benzamida. - Google Patents

Formulacion de liberacion inmediata de 4 - metil - 3 - [ [4- (3-piridinil) - 2 - pirimidinil] - amino] - n - [5 - (4 - metil - 1h - imidazol - 1 - il) - 3 - (trifluoro-metil) - fenil] - benzamida.

Info

Publication number
MX2014005874A
MX2014005874A MX2014005874A MX2014005874A MX2014005874A MX 2014005874 A MX2014005874 A MX 2014005874A MX 2014005874 A MX2014005874 A MX 2014005874A MX 2014005874 A MX2014005874 A MX 2014005874A MX 2014005874 A MX2014005874 A MX 2014005874A
Authority
MX
Mexico
Prior art keywords
methyl
imidazol
pyridinyl
pyrimidinyl
trifluoromethyl
Prior art date
Application number
MX2014005874A
Other languages
English (en)
Spanish (es)
Inventor
Upkar Bhardwaj
Ann Reese Comfort
Ping Li
Shoufeng Li
Alexey Makarov
Mangesh Sadashiv Bordawekar
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2014005874A publication Critical patent/MX2014005874A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2014005874A 2011-11-14 2012-11-12 Formulacion de liberacion inmediata de 4 - metil - 3 - [ [4- (3-piridinil) - 2 - pirimidinil] - amino] - n - [5 - (4 - metil - 1h - imidazol - 1 - il) - 3 - (trifluoro-metil) - fenil] - benzamida. MX2014005874A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161559281P 2011-11-14 2011-11-14
PCT/US2012/064610 WO2013074432A1 (fr) 2011-11-14 2012-11-12 Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide

Publications (1)

Publication Number Publication Date
MX2014005874A true MX2014005874A (es) 2014-06-23

Family

ID=47324402

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005874A MX2014005874A (es) 2011-11-14 2012-11-12 Formulacion de liberacion inmediata de 4 - metil - 3 - [ [4- (3-piridinil) - 2 - pirimidinil] - amino] - n - [5 - (4 - metil - 1h - imidazol - 1 - il) - 3 - (trifluoro-metil) - fenil] - benzamida.

Country Status (22)

Country Link
EP (1) EP2779995A1 (fr)
JP (1) JP6275645B2 (fr)
KR (1) KR20140093230A (fr)
CN (1) CN103930094A (fr)
AR (1) AR088844A1 (fr)
BR (1) BR112014011518A2 (fr)
CA (1) CA2855503A1 (fr)
CL (1) CL2014001247A1 (fr)
CO (1) CO6960546A2 (fr)
EA (1) EA201490960A1 (fr)
GT (1) GT201400094A (fr)
HK (1) HK1197025A1 (fr)
IL (1) IL232480A0 (fr)
IN (1) IN2014DN03416A (fr)
MA (1) MA35636B1 (fr)
MX (1) MX2014005874A (fr)
PE (1) PE20141337A1 (fr)
SG (2) SG10201707768RA (fr)
TN (1) TN2014000177A1 (fr)
TW (1) TWI574690B (fr)
WO (1) WO2013074432A1 (fr)
ZA (1) ZA201402756B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2792360A1 (fr) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide pour utilisation dans le traitement de HCV
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
JP7378279B2 (ja) * 2019-11-18 2023-11-13 日本化薬株式会社 ニロチニブを有効成分とする医薬錠剤及びその製造方法
JP7489849B2 (ja) 2020-07-20 2024-05-24 日本化薬株式会社 ニロチニブ錠剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
EP1923053A1 (fr) * 2006-09-27 2008-05-21 Novartis AG Composition pharmaceutique comprenant de la nilotinib ou son sel
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
IN2011CH01887A (fr) * 2011-06-02 2012-12-14

Also Published As

Publication number Publication date
WO2013074432A1 (fr) 2013-05-23
CN103930094A (zh) 2014-07-16
CO6960546A2 (es) 2014-05-30
IN2014DN03416A (fr) 2015-06-26
JP6275645B2 (ja) 2018-02-07
TN2014000177A1 (en) 2015-09-30
EP2779995A1 (fr) 2014-09-24
AU2012339829A1 (en) 2014-05-29
NZ623844A (en) 2016-09-30
SG10201707768RA (en) 2017-10-30
SG11201401476TA (en) 2014-10-30
AR088844A1 (es) 2014-07-10
AU2012339829B2 (en) 2016-05-12
EA201490960A1 (ru) 2014-08-29
CA2855503A1 (fr) 2013-05-23
GT201400094A (es) 2017-09-28
HK1197025A1 (en) 2015-01-02
MA35636B1 (fr) 2014-11-01
BR112014011518A2 (pt) 2017-05-16
IL232480A0 (en) 2014-06-30
PE20141337A1 (es) 2014-10-16
TWI574690B (zh) 2017-03-21
JP2014533283A (ja) 2014-12-11
ZA201402756B (en) 2015-04-29
TW201325594A (zh) 2013-07-01
KR20140093230A (ko) 2014-07-25
CL2014001247A1 (es) 2014-10-17

Similar Documents

Publication Publication Date Title
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
EA201291421A1 (ru) Пероральные фармацевтические лекарственные формы, содержащие дабигатрана этексилат и его фармацевтически приемлемые соли
PH12016501310A1 (en) Pharmaceutical compositions comprising azd9291
IL229199A (en) N– (2– {2– dimethylaminoethyl-methylamino} –4 – methoxy-5 - {[4– (1-methylindol-3-yl) pyrimidine-2-yl] amino} phenyl) prop-2-anamide and salts acceptable in pharmacy Her, pharmaceuticals that include her and its use in the manufacture of cancer drugs
PH12014501277A1 (en) Kinase inhibitors
MX2021002264A (es) Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
CL2012001270A1 (es) Compuesto 4-metil-n-[3-(4-metil-1h-imidazol-1-il)-5-(trifluorometil)fenil]-3-[(4-piridin-3-ilpirimidin-2-il)amino] benzamida (nilotinib) para el tratamiento de un trastorno proliferativo u otras condiciones mediadas por quinasa bcr-abl, c-kit, ddr1, ddr2 o pdgf-r, administrado oralmente dispersado en una compota de manzana.
PH12014501278A1 (en) Kinase inhibitors
TN2014000177A1 (en) Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation
NZ590839A (en) Treatment of pulmonary arterial hypertension
NZ597864A (en) Methods and compositions for treating leukemia
TN2013000440A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
TH152470A (th) สูตรตำรับ 4-เมธิล-3-[[4-(3-ไพริดินิล-2-ไพริมิดินิลอะมิโน1-n-[5-(4-เมธิล-1h-อิมิดาโซล-1-อิล)-3-(ไตรฟลูออโรเมธิล)ฟีนิล] เบนซาไมด์ชนิดปลดปล่อยทันที